MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
艰难梭菌的微生物群依赖性控制:乙酸盐和 IL-22 结合蛋白的作用
基本信息
- 批准号:10539270
- 负责人:
- 金额:$ 41.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:16S ribosomal RNA sequencingAcetatesAddressAntibiotic TherapyBacteriaBinding ProteinsBiological AvailabilityBrazilCell Surface ReceptorsCessation of lifeChemotactic FactorsClostridium difficileColectomyCollaborationsDataDiarrheaEpithelial CellsFFAR2 geneGene Expression ProfileGenetic TranscriptionGerm-FreeGoalsGrowthHealthHospitalizationHost DefenseHumanImmune responseIn VitroIncidenceInfectionInfection preventionInflammasomeInterleukin-1 betaIntestinesJointsLaboratoriesLymphoidLymphoid CellMediatingMetabolismMucosal Immune ResponsesMucous MembraneMusNatural ImmunityNeutrophil ActivationNeutrophil InfiltrationOrganogenesisPatientsPlayProductionProductivityProtein DeficiencyPseudomembranous ColitisRecurrenceRegulationResistanceRoleSecureSeveritiesSignal TransductionSurfaceTestingTherapeuticTherapeutic InterventionTimeToxic MegacolonToxinTranslatingTreatment FailureVolatile Fatty AcidsWorkantimicrobialantimicrobial peptidecell typecohortdysbiosisexperimental studyfecal transplantationforgingfundamental researchgut microbiotahigh riskin vivoinnovationinterleukin-22intestinal epitheliummetabolomicsmicrobialmicrobiotamortalityneutrophilnovelprotective effectreceptorresponsesynergismtranscriptometranslational potential
项目摘要
PROJECT SUMMARY
The overall goal of this application is to establish avenues through which we can harness the intestinal microbiota
to enhance mucosal immune responses against Clostridium difficile. C. difficile infection (CDI) is a common
cause of diarrhea in hospitalized patients and represents a major health threat due to frequent treatment failures
and high risks of colectomy and mortality. Patients with recurrent CDI do not benefit from conventional
antimicrobial therapies; while transplantation of fecal microbiota derived from healthy donors might be a valid
option, regulation of fecal transplantation is problematic. In our preliminary data we show for the first time a
remarkable impact of microbiota-derived acetate on CDI, which may constitute a potential therapeutic avenue.
We show that acetate enhances neutrophil and innate lymphoid cells of type 3 (ILC3) responses through the
surface receptor FFAR2. Moreover, we show that lack of a decoy receptor for IL-22, known as IL-22 binding
protein (IL-22BP), amplifies the activity of IL-22 and modifies the microbiota, strengthening its resistance to CDI.
We propose three specific aims. In Specific Aim 1, we will test the mechanisms through which acetate-FFAR2
signaling activates the neutrophil response to CDI. We will perform in vitro functional and transcriptional
experiments to determine whether FFAR2 promotes neutrophil recruitment to chemoattractants, upregulates
expression of inflammasome components, alters the neutrophil transcriptional profile, and/or modifies neutrophil
metabolism. The impact of acetate on human neutrophils will be examined as well. In Specific Aim 2, using newly
generated mice lacking FFAR2 in ILC3s, along with mice lacking FFAR2 in neutrophils, we will determine
whether FFAR2 mediated activation of ILC3s is necessary and sufficient to recapitulate the protective effect of
acetate in vivo. Furthermore, we will determine whether FFAR2 impacts ILC3-mediated lymphoid organogenesis
in the steady state and whether FFAR2 modifies the transcriptome and/or metabolism of mouse and human
ILC3s. Finally, we will ascertain whether acetate can be used in a therapeutic mode. In Specific Aim 3, we will
test the hypothesis that lack of IL-22BP and the resulting increased basal activity of IL-22 modify the intestinal
microbiota in a manner that facilitates the colonization of bacterial cohorts that enhance protection against CDI.
This work is significant because it addresses the major health burden of dysbiosis and CDI, is innovative because
it evaluates alternative therapeutic approaches based on acetate and/or blockade of IL-22BP rather than live
microbiota and has potential to translate into novel treatments with implications for health and productivity. The
project will be accomplished through the ongoing collaboration between the Colonna lab in USA and the Vinolo
lab in Brazil, each with distinct and complementary sets of expertise on CDI, short chain fatty acids, and mucosal
innate immunity that must be combined to successfully complete this project. The synergy between the two labs
has already generated results that serve as the basis for this proposal and will produce fundamental research
on the impact of the microbiota on mucosal responses to CDI and unveil new potential therapies.
项目摘要
这个应用程序的总体目标是建立途径,通过它我们可以利用肠道微生物群
以增强针对艰难梭菌的粘膜免疫应答。C.艰难梭菌感染(CDI)是常见的
腹泻是住院患者腹泻的主要原因,由于频繁的治疗失败,
结肠切除术和死亡的风险很高。复发性CDI患者不能从常规治疗中获益
抗微生物治疗;而移植来自健康供体的粪便微生物群可能是有效的
选择,粪便移植的监管存在问题。在我们的初步数据中,我们首次显示了
微生物来源的乙酸盐对CDI的显著影响,这可能构成潜在的治疗途径。
我们发现,醋酸盐通过增强中性粒细胞和3型先天淋巴细胞(ILC 3)的反应,
表面受体FFAR 2。此外,我们发现缺乏IL-22的诱饵受体,称为IL-22结合,
IL-22蛋白(IL-22 BP),放大IL-22的活性并修饰微生物群,增强其对CDI的抵抗力。
我们提出三个具体目标。在具体目标1中,我们将测试醋酸-FFAR 2
信号传导激活嗜中性粒细胞对CDI的应答。我们将进行体外功能和转录
实验以确定FFAR 2是否促进中性粒细胞募集到化学引诱物,上调
炎性体组分的表达,改变嗜中性粒细胞转录谱,和/或修饰嗜中性粒细胞
新陈代谢.还将检查醋酸盐对人中性粒细胞的影响。在具体目标2中,
产生ILC 3中缺乏FFAR 2的小鼠,沿着中性粒细胞中缺乏FFAR 2的小鼠,我们将确定
FFAR 2介导的ILC 3激活是否是必需的,是否足以概括FFAR 2的保护作用。
体内醋酸盐。此外,我们将确定FFAR 2是否影响ILC 3介导的淋巴器官发生,
以及FFAR 2是否改变小鼠和人的转录组和/或代谢
ILC3。最后,我们将确定醋酸盐是否可以用于治疗模式。在具体目标3中,我们
测试缺乏IL-22 BP和由此产生的IL-22基础活性增加改变肠内
在一些实施方案中,本发明的组合物以促进细菌群的定殖的方式促进微生物群,从而增强对CDI的保护。
这项工作是重要的,因为它解决了生态失调和CDI的主要健康负担,是创新的,因为
它评估了基于醋酸盐和/或IL-22 BP阻断而不是肝的替代治疗方法,
微生物群,并有可能转化为对健康和生产力有影响的新疗法。的
该项目将通过美国科隆纳实验室和Vinolo之间的持续合作来完成
巴西的一个实验室,每个实验室在CDI、短链脂肪酸和粘膜方面都有独特和互补的专业知识
先天免疫必须结合起来才能成功完成这个项目。两个实验室之间的协同作用
已经产生的结果作为这项建议的基础,并将产生基础研究
研究微生物对粘膜对CDI反应的影响,并揭示新的潜在疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARCO COLONNA其他文献
MARCO COLONNA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARCO COLONNA', 18)}}的其他基金
Mucosal Immune Defense Mechanisms of the Urinary Bladder
膀胱粘膜免疫防御机制
- 批准号:
10587639 - 财政年份:2023
- 资助金额:
$ 41.03万 - 项目类别:
Soluble TREM2 regulation of microglial function in Alzheimer disease
可溶性 TREM2 对阿尔茨海默病小胶质细胞功能的调节
- 批准号:
10432584 - 财政年份:2022
- 资助金额:
$ 41.03万 - 项目类别:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
多胺对稳态和结肠炎临床前模型中 ILC3 功能的影响
- 批准号:
10528082 - 财政年份:2022
- 资助金额:
$ 41.03万 - 项目类别:
The protein tyrosine kinase SYK drives innate immune responses against Alzheimer's Disease
蛋白质酪氨酸激酶 SYK 驱动针对阿尔茨海默病的先天免疫反应
- 批准号:
10674689 - 财政年份:2022
- 资助金额:
$ 41.03万 - 项目类别:
Impact of polyamines on ILC3 function at steady state and in preclinical model of colitis
多胺对稳态和结肠炎临床前模型中 ILC3 功能的影响
- 批准号:
10623342 - 财政年份:2022
- 资助金额:
$ 41.03万 - 项目类别:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
CNS 边界 B 细胞在稳态、衰老和自身免疫中的个体发育生态位
- 批准号:
10446266 - 财政年份:2022
- 资助金额:
$ 41.03万 - 项目类别:
Ontogenetic niche of B cells at the CNS borders in homeostasis, aging and autoimmunity
CNS 边界 B 细胞在稳态、衰老和自身免疫中的个体发育生态位
- 批准号:
10557870 - 财政年份:2022
- 资助金额:
$ 41.03万 - 项目类别:
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEIN
艰难梭菌的微生物群依赖性控制:乙酸盐和 IL-22 结合蛋白的作用
- 批准号:
10321553 - 财政年份:2021
- 资助金额:
$ 41.03万 - 项目类别:
Targeting TREM2 to boost anti-cancer therapy
靶向 TREM2 促进抗癌治疗
- 批准号:
10477296 - 财政年份:2021
- 资助金额:
$ 41.03万 - 项目类别:
Targeting TREM2 to boost anti-cancer therapy
靶向 TREM2 促进抗癌治疗
- 批准号:
10279674 - 财政年份:2021
- 资助金额:
$ 41.03万 - 项目类别:
相似海外基金
Development of palladium-catalyzed novel organic transformations of silylated allyl acetates
钯催化的硅烷化乙酸烯丙酯新型有机转化的开发
- 批准号:
18K05101 - 财政年份:2018
- 资助金额:
$ 41.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Biosynthesis of Methylketones and 2-Alkany l Acetates
甲基酮和 2-烷酰基乙酸酯的生物合成
- 批准号:
9118188 - 财政年份:1992
- 资助金额:
$ 41.03万 - 项目类别:
Standard Grant